ClinicalTrials.gg
Active, not recruitingNCT05636709GRACEUpdated Nov 4, 2026

National GMA Post-market Clinical Follow-up Study (GRACE)

An observational study in Crohn Disease and Ulcerative Colitis, sponsored by Adacyte Therapeutics SL. Active, not recruiting at 30 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Adacyte Therapeutics SL · Observational

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Crohn Disease with a site in Spain — 32 open to participants now, 51 under way, 28 of them phase 3. Crohn Disease · Spain.

Planned enrollment
15th of 31
350 · median 350
Started
2022
with 11 others
Observational
31 of 181
5 open now
Primary completion
2027-06
later than 16 of 50 live
Registered
138th of 181
by date

Among the 181 studies in Crohn Disease with a site in Spain, this one is the 15th largest by planned enrollment of the 31 observational ones that give a count, is one of 12 that started in 2022, is one of 31 observational ones, reaches primary completion later than 16 of the 50 other live ones, and was the 138th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

32 of the 181 studies in Crohn Disease with a site in Spain are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Crohn Disease with a site in Spain, or all of them as a file.
02

Study summary

Inflammatory bowel disease (IBD) encompasses several chronic diseases of which ulcerative colitis (UC) and Crohn's disease (CD) are the most representative. IBD is characterised by the presence of an inflammatory process that affects different segments of the digestive tract and has a chronic and relapsing course with flares of activity.

Inflammatory activity in IBD is associated with an increase in peripheral blood activated granulocytes and monocyte-macrophages and intestinal infiltration by these inflammatory cells, which are largely responsible for tissue damage. In recent years, observational, prospective studies and meta-analyses of these studies have contributed to consider granulocytapheresis (GMA) as an effective and safe alternative in the treatment of UC.

This apheresis technique is based on recirculation of the patient's blood through a circuit with cellulose acetate spheres that perform a selective elimination of granulocytes and monocyte-macrophages leading to a reduction in pro-inflammatory cytokines and adhesion molecule expression, and an increase in anti-inflammatory mediators. These events in the GMA column are followed by other immunological changes, most notably a decrease in CD10+ (activated) neutrophils, leading to a compensation from the bone marrow of a CD10- (immature) neutrophil population.

GMA can be considered as a therapeutic alternative in corticodependent IBD, especially in UC. In addition, it can reduce or limit the need for corticosteroids, so another possible application is as a "bridge" treatment in patients starting treatment with thiopurine immunomodulators. A beneficial effect can also be obtained by combining apheresis with biological treatments, especially after a partial response or loss of response to these treatments. Finally, some extraintestinal manifestations associated with IBD may also benefit from its use.

The GRACE study is proposed for the evaluation of the efficacy of GMA with Adacolumn® under real conditions of use and according to the indications described in the instructions for use of the medical device.

Read the detailed description

It is planned to enrol a minimum of 350 patients from approximately 30 sites. To avoid screening biases, the patients to be included per site will be selected consecutively from among those who meet the eligibility criteria to participate in the study.

A national, multicentre, noninterventional post-market clinical follow-up (PMCF) study with an estimated follow-up period of 12 months after completion of GMA therapy to evaluate the efficacy of Adacolumn® GMA in actual conditions of use, as specified in the product instructions for use, in adult patients diagnosed with UC or CD. Approximately 350 patients from about 30 centres in Spain are planned to be included.

The standard regimen according to product instructions for use is one session per week for 5 consecutive weeks, although in specific cases continuous regimens have been established for maintenance (one or two sessions per month) or others for induction (two sessions per week). The use of a higher number of sessions seems to increase efficacy from 40% with 5 sessions to 80% with 10 in the more refractory cases and may achieve a greater reduction in steroid use. In Europe, where GMA is used in different scenarios, it is routinely being used in 7 to 10 sessions.

The study will consist of a maximum of 4 visits: a baseline visit, which will coincide with patient inclusion in the study, and 3 follow-up visits at 4 (±2 weeks) (month 1), 24 (±2 weeks) (month 6) and 48 (±2 weeks) (month 12) weeks after the last session of induction apheresis.

All visits scheduled during the study will coincide with any of the patient visits made as part of routine clinical follow-up, without interfering with the investigator's clinical duties. Note: In the event that a patient discontinues Adacolumn® GMA, the reasons for discontinuation of the procedure will be recorded and the change in treatment for IBD, if any.

Once the patient has been adequately informed, his/her eligibility has been confirmed and he/she has signed the informed consent (IC), the investigator will start data collection in an appropriate and precise manner. Therefore, no diagnostic or therapeutic intervention outside of routine clinical practice will be applied. To ensure the noninterventional nature of the study, the data will be collected provided they are available in the patient's medical record or can be collected during patient visits to his/her physician as part of actual clinical care (as in the case of questionnaires used as source documents).

Adacolumn® is a medical device intended for modifying the biological or chemical composition of the blood (class IIb), according to Regulation (UE) 2017/745 on Medical Devices, manufactured by Japan Immnunoresearch Laboratories, JIMRO (Takasaki, Japan). It consists of a 335 ml column formed by cellulose acetate beads of 2 mm in diameter bathed in saline, where granulocytes (65%), monocytes (55%), and only 2% of lymphocytes are selectively adsorbed.

Adacolumn® is indicated for induction of remission in patients with IBD (active UC and CD), for suppression of subjective and objective symptoms in patients with rheumatoid arthritis in the inflammatory stage whose symptoms might be resistant to standard drug therapy, for treatment of patients with ocular Behcet disease and for treatment of patients with systemic lupus erythematosus.

In this study, the intended use of Adacolumn® is for application of GMA in patients diagnosed with IBD, both UC and CD

03

Conditions studied

  • Crohn Disease
  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients diagnosed with Ulcerosis Colitis or Crohn disease from about 30 centres in Spain in whom the physician in charge of treatment decides to start treatment with GMA and independently of their inclusion in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years.
  2. Established diagnosis of UC or CD according to ECCO criteria.
  3. Patients in whom the physician in charge of treatment decides to start treatment with GMA and independently of their inclusion in the study.
  4. Patients who understand and voluntarily sign .

Exclusion criteria

Exclusion Criteria:

  1. Patient with any medical or psychological disorder that, in the investigator's opinion, may interfere with the patient's ability to comply with the study procedures.
  2. Patient who is participating in a clinical trial.

NOTE: If the physician knows or suspects that the patient is unable to understand the implications of his/her participation in the study, the patient should not enter without the signature of his/her legal representative

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Interventions

  • DeviceAdacolumn

    Non interventional study

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving steroid-free clinical remission at 6 months after completion of GMA therapy

    Proportion of patients achieving steroid-free clinical remission at 6 months after completion of GMA therapy. Clinical remission is defined as: 1. For Ulcerative Colitis: Total Mayo score ≤2, with no subscore \>1 and rectal bleeding subscore of 0. 2. For Crohn´s Disease: Harvey-Bradshaw Index score ≤4. Mayor score (0-12). Higher scores mean a worse outcome. Harvey-Bradshaw Index (0-undetermined). Higher scores mean a worse outcome.

    Time frame: 6 months

Secondary outcomes

  1. Define the regimens used for GMA in actual clinical practice.

    The strategies for use of GMA will be evaluated by the following: * Frequency of GMA sessions, Number of sessions, Blood volume processed per session in ml, Length of sessions in minutes, Method of administration of the technique (peripheral access or central catheter), Type of anticoagulant (Heparin, sodic heparin, low molecular weight heparin), Dose of anticoagulant (ml), Form of administration (infusion or bolus). * Proportion of patients receiving GMA treatment combined with biologics or immunosuppressants as bridge treatment after instituting treatment with immunomodulators due to lack of response or intolerance to immunosuppressants and/or biologics or as an alternative to conventional treatment. * Proportion of patients with steroid-dependent or steroid-refractory disease receiving GMA. * Proportion of patients receiving GMA as treatment for remission induction or relapse prevention. * Proportion of patients receiving GMA as maintenance treatment

    Time frame: 12 months

  2. Early clinical remission rate

    Proportion of patients achieving steroid-free clinical remission at 1 month after completion of GMA therapy Clinical remission is defined as: 1. For Ulcerative Colitis: Total Mayo score ≤2, with no subscore \>1 and rectal bleeding subscore of 0. 2. For Crohn´s Disease: Harvey-Bradshaw Index score ≤4. Mayor score (0-12). Higher scores mean a worse outcome. Harvey-Bradshaw Index (0-undetermined). Higher scores mean a worse outcome.

    Time frame: 1 month

  3. 6- and 12-month remission rates completion of GMA therapy

    Proportion of patients achieving steroid-free clinical remission at 12 months after completion of GMA therapy Clinical remission is defined as: 1. For Ulcerative Colitis: Total Mayo score ≤2, with no subscore \>1 and rectal bleeding subscore of 0. 2. For Crohn´s Disease: Harvey-Bradshaw Index score ≤4. Mayor score (0-12). Higher scores mean a worse outcome. Harvey-Bradshaw Index (0-undetermined). Higher scores mean a worse outcome.

    Time frame: 6 and 12-month

  4. Sustained clinical remission rate

    Proportion of patients maintaining clinical remission at 12 months after completion of GMA therapy Clinical remission at 12 months is defined as: 1. For Ulcerative Colitis: Total Mayo score ≤2, with no subscore \>1 and rectal bleeding subscore of 0. 2. For Crohn´s Disease: Harvey-Bradshaw Index score ≤4. Until 12 months Mayor score (0-12). Higher scores mean a worse outcome. Harvey-Bradshaw Index (0-undetermined). Higher scores mean a worse outcome.

    Time frame: 12 months

  5. 6- and 12-month clinical response rates

    Proportion of patients with clinical response at 6 and 12 months after completion of GMA therapy, defined as a reduction of 3 o more points or 30% in the Mayo score for Ulcerative Colitis, or 3 or more points in the Harvey Bradshaw index for Crohn´s Disease Mayor score (0-12) Harvey-Bradshaw Index (0-undetermined) Higher scores mean a worse outcome.

    Time frame: 6 and 12-month

  6. Rate of patients receiving GMA as maintenance and its efficacy

    Proportion of patients on maintenance treatment remaining in steroid-free clinical remission at 6 (visit 3) and 12 (visit 4) months after completion of therapy Clinical remission is defined as: 1. For Ulcerative Colitis: Total Mayo score ≤2, with no subscore \>1 and rectal bleeding subscore of 0. 2. For Crohn´s Disease: Harvey-Bradshaw Index score ≤4. At 6 months and 12 months Mayor score (0-12). Higher scores mean a worse outcome. Harvey-Bradshaw Index (0-undetermined). Higher scores mean a worse outcome.

    Time frame: 12 months

  7. Rate of patients requiring steroids and mean dose during follow-up

    * Rate of patients requiring steroids * Mean dose of steroids Steroids in mg

    Time frame: 12 months

  8. Changes in faecal calprotectin and C-reactive protein (CRP) biomarkers during treatment

    The change in biomarkers levels (faecal calprotectin (microg/g or mg/Kg) and CRP (mg/L)) will be evaluated by laboratory tests performed at the baseline visit (visit 1), at each apheresis session, at 1 month after completion of treatment (visit 2) and at 6 (visit 3) and 12 months (visit 4) after completion of treatment.

    Time frame: 12 months

  9. Rate of treatment-related adverse events (AEs) and seriousness

    Frequency of treatment-related AEs and seriousness

    Time frame: 6 months

  10. Change in patients' quality of life

    The change in quality of life will be evaluated by the validated version in Spanish of the Inflammatory Bowel Disease Questionnaire, which will be completed by the patient at the baseline visit (visit 1), at each apheresis session, at 1, (visit 2), 6 (visit 3) and 12 months (visit 4) after completion of treatment Inflammatory Bowel Disease Questionnaire (0-100) Higher scores mean a better outcome.

    Time frame: 6 months

  11. Number of patients requiring surgery

    Proportion of patients requiring surgery during the study period (UC: colectomy, segmental colonic resection, perianal; CD: small intestine resection, colonic resection, ileocecal resection, perianal resection).

    Time frame: 6 months

07

Study locations

30 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jun 2027, 65 months after the start.

Of 73 industry-sponsored observational studies under Crohn Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 60. This study's planned 65 months is above that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Dec 5, 2022
StartActual
Jan 11, 2022
Primary completionEst.
Jun 30, 2027was Jun 2026
CompletionEst.
Jun 30, 2027was Jun 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Sites
24 sites added, 24 sites removed
Show 24 added (24 Spain)
  • H. Albacete · Albacete, Spain
  • H. General de Alicante · Alicante, Spain
  • H. Vall d´hebron · Barcelona, Spain
  • H. General de Castellón · Castellon, Spain
  • H. Puerta del Mar · Cadiz, Spain
  • H. Reina Sofía · Córdoba, Spain
  • H. Virgen de las Nieves · Granada, Spain
  • H. Guadalajara · Guadalajara, Spain
  • H. San Jorge · Huesca, Spain
  • H. Santiago · Santiago de Compostela, Spain
  • H. Dr. Negrín · Las Palmas de Gran Canaria, Spain
  • H. 12 de octubre · Madrid, Spain
  • H. La Paz · Madrid, Spain
  • H. Navarra · Pamplona, Spain
  • H. Río Carrión · Palencia, Spain
  • H. Son Espases · Palma de Mallorca, Spain
  • H. Son Llatzer · Palma de Mallorca, Spain
  • H. Univ. de Canarias · San Cristóbal de La Laguna, Spain
  • H. Ntra. Sra. de Candelaria · Santa Cruz de Tenerife, Spain
  • H. Virgen del Rocío · Seville, Spain
  • H. Clínico Univ. de Valencia · Valencia, Spain
  • H. General de Valencia · Valencia, Spain
  • H. La Fe · Valencia, Spain
  • H. Virgen de la Concha · Zamora, Spain
Show 24 removed
  • H. General de Castellón · Castelló de la Plana, Spain
  • H. Santiago · Santiago De Compostela, Spain
  • H. Dr. Negrín · Las Palmas De Gran Canaria, Spain
  • H. Navarra · Pamplona, Spain
  • H. Univ. de Canarias · La Laguna, Spain
  • H. Albacete · Albacete, Spain
  • H. General de Alicante · Alicante, Spain
  • H. Vall d´hebron · Barcelona, Spain
  • H. Puerta del Mar · Cádiz, Spain
  • H. Reina Sofía · Córdoba, Spain
  • H. Virgen de las Nieves · Granada, Spain
  • H. Guadalajara · Guadalajara, Spain
  • H. San Jorge · Huesca, Spain
  • H. 12 de octubre · Madrid, Spain
  • H. La Paz · Madrid, Spain
  • H. Río Carrión · Palencia, Spain
  • H. Son Espases · Palma De Mallorca, Spain
  • H. Son Llatzer · Palma de Mallorca, Spain
  • H. Ntra. Sra. de Candelaria · Santa Cruz De Tenerife, Spain
  • H. Virgen del Rocío · Sevilla, Spain
  • H. Clínico Univ. de Valencia · Valencia, Spain
  • H. General de Valencia · Valencia, Spain
  • H. La Fe · Valencia, Spain
  • H. Virgen de la Concha · Zamora, Spain
Nov 4, 2026
Primary completion
Jun 30, 2026→Jun 30, 2027
Nov 4, 2026
Study completion
Jun 30, 2026→Jun 30, 2027
Nov 4, 2026
Eligibility
Revised
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    24 sites added, 24 sites removed
    Show 24 added (24 Spain)
    • H. Albacete · Albacete, Spain
    • H. General de Alicante · Alicante, Spain
    • H. Vall d´hebron · Barcelona, Spain
    • H. General de Castellón · Castellon, Spain
    • H. Puerta del Mar · Cadiz, Spain
    • H. Reina Sofía · Córdoba, Spain
    • H. Virgen de las Nieves · Granada, Spain
    • H. Guadalajara · Guadalajara, Spain
    • H. San Jorge · Huesca, Spain
    • H. Santiago · Santiago de Compostela, Spain
    • H. Dr. Negrín · Las Palmas de Gran Canaria, Spain
    • H. 12 de octubre · Madrid, Spain
    • H. La Paz · Madrid, Spain
    • H. Navarra · Pamplona, Spain
    • H. Río Carrión · Palencia, Spain
    • H. Son Espases · Palma de Mallorca, Spain
    • H. Son Llatzer · Palma de Mallorca, Spain
    • H. Univ. de Canarias · San Cristóbal de La Laguna, Spain
    • H. Ntra. Sra. de Candelaria · Santa Cruz de Tenerife, Spain
    • H. Virgen del Rocío · Seville, Spain
    • H. Clínico Univ. de Valencia · Valencia, Spain
    • H. General de Valencia · Valencia, Spain
    • H. La Fe · Valencia, Spain
    • H. Virgen de la Concha · Zamora, Spain
    Show 24 removed
    • H. General de Castellón · Castelló de la Plana, Spain
    • H. Santiago · Santiago De Compostela, Spain
    • H. Dr. Negrín · Las Palmas De Gran Canaria, Spain
    • H. Navarra · Pamplona, Spain
    • H. Univ. de Canarias · La Laguna, Spain
    • H. Albacete · Albacete, Spain
    • H. General de Alicante · Alicante, Spain
    • H. Vall d´hebron · Barcelona, Spain
    • H. Puerta del Mar · Cádiz, Spain
    • H. Reina Sofía · Córdoba, Spain
    • H. Virgen de las Nieves · Granada, Spain
    • H. Guadalajara · Guadalajara, Spain
    • H. San Jorge · Huesca, Spain
    • H. 12 de octubre · Madrid, Spain
    • H. La Paz · Madrid, Spain
    • H. Río Carrión · Palencia, Spain
    • H. Son Espases · Palma De Mallorca, Spain
    • H. Son Llatzer · Palma de Mallorca, Spain
    • H. Ntra. Sra. de Candelaria · Santa Cruz De Tenerife, Spain
    • H. Virgen del Rocío · Sevilla, Spain
    • H. Clínico Univ. de Valencia · Valencia, Spain
    • H. General de Valencia · Valencia, Spain
    • H. La Fe · Valencia, Spain
    • H. Virgen de la Concha · Zamora, Spain
    Primary completion Jun 30, 2026→Jun 30, 2027
    Study completion Jun 30, 2026→Jun 30, 2027
    Eligibility Revised
    + 6 other changes: index terms, identifiers, verification date, oversight details, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05636709
Lead sponsor
Adacyte Therapeutics SL
Responsible party
Sponsor
First posted
Dec 5, 2022
Start date
Jan 11, 2022
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Jose Luis Cabriada
study chair · H. Galdakao
Iago Rodríguez
study chair · H. Galdakao
Daniel Ginard
study chair · H. Son Espases

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion